Anti-Human CD20 Reference Antibody (Ocrelizumab, RUO)

Description: Ocrelizumab (BS10623) is a research-grade recombinant antibody targeting CD20. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-nd
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 4.13mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: B-lymphocytesurfaceantigenB1,Membrane-spanning4-domainssubfamilyAmember1,MS4A1,LeukocytesurfaceantigenLeu-16,B-lymphocyteantigenCD20,Bp35,CD20
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: 2H7,PR-070769/PR070769/R-1594/RG-1594,CAS:637334-45-3
Background: Ofatumumab is a fully human anti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity in CD20-expressing B lymphocytes.
Note: For research use only. Not suitable for clinical or therapeutic use.